NCT00139919

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Either Schizophrenia or Bipolar Disorder With an Optional Open-Label 26-Week Extension Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an optional open-label 26-week extension study.

Conditions

• Schizophrenia
• Schizoaffective Disorder
• Bipolar Disorder

Interventions

Type	Name	Description
DRUG	Bifeprunox

Timeline

• Start date: 2006-01-01
• Primary completion: 2007-10-01
• Completion: 2007-10-01
• First posted: 2005-08-31
• Last updated: 2015-01-16

Locations

1 site across 1 country: United States